- cafead   Aug 14, 2019 at 11:12: AM
via With investors getting jittery about the durability of Jazz Pharma’s cash-cow Xyrem, the specialty biopharmaceutical drugmaker is expanding its portfolio with the purchase of Cavion, a biotechnology company focused on rare, chronic neurological diseases.
article source
article source